At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
CT-P59 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating CT-P59 and Placebo for SARS-CoV-2 Infection. Completed, enrolled 32 participants across 1 site.
Detailed Summary
This is a Phase I study that randomized, double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to evaluate Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2 Infection
CountriesSouth Korea
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
Enrollment StartJul 2020
Primary CompletionAug 2020
First PostedAug 2020
Study CompletionNov 2020
TodayJul 2026
First PostedAug 25, 2020
Enrollment StartJul 18, 2020
Primary CompletionAug 7, 2020
Study CompletionNov 5, 2020
TodayJul 2, 2026
Enrollment to primary: 19 daysPosted 5.9 years ago
Interventions
CT-P59drug
CT-P59 will be administered
Placebodrug
Placebo-matching CT-P59